BCL2L12 is a Novel Biomarker for the Prediction of Short-Term Relapse in Nasopharyngeal Carcinoma

Table 4 BCL2L12 mRNA expression and nasopharyngeal carcinoma survival.

	DFS			OS
Hazard ratio^a	95% Cl^b	P	Hazard ratio^a	95% Cl^b	P
Univariate analysis
BCL2L12 mRNA
Negative	1.00			1.00
Positive	6.82	1.62–28.57	0.017	2.72	0.77–9.52	0.11
Tumor extent^c (ordinal)	1.41	0.77–2.54	0.27	1.17	0.66–2.07	0.58
Histology^d	0.31	0.085–1.06	0.063	0.65	0.19–2.17	0.49
(undifferentiated/nonkeratinizing)
Multivariate analysis^e
BCL2L12 mRNA
Negative	1.00			1.00
Positive	4.78	1.056–21.67	0.042	2.36	0.61–9.23	0.21
Tumor extent^c (ordinal)	1.18	0.63–2.23	0.59	1.06	0.59–1.91	0.84
Histology^d	0.44	0.11–1.74	0.24	0.86	0.23–3.11	0.825
(undifferentiated/nonkeratinizing)

^aHazard ratio, estimated from Cox proportional hazard regression model.
^bConfidence interval of the estimated hazard ratio.
^cStaging system, established by the American Joint Committee on Cancer (21,22).
^dHistology classification system, established by the World Health Organization.
^eMultivariate models were adjusted for sex, age, tumor extent and histology.

ISSN: 1528-3658